Identifying biomarkers for blood clot risks in multiple myeloma patients
Evaluation of Predictive Biomarkers in de Novo Multiple Myeloma on the Onset of Venous Thromboembolism, Its Impact on Clinical Outcome and Thromboprophylaxis (VESICOM)
NA · Centre Hospitalier Universitaire de Saint Etienne · NCT05259553
This study is testing if certain blood markers can help identify multiple myeloma patients who are at higher risk for blood clots during treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne (other) |
| Locations | 2 sites (Lyon and 1 other locations) |
| Trial ID | NCT05259553 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between multiple myeloma and the increased risk of venous thromboembolism (VTE) in newly diagnosed patients. It aims to identify predictive biomarkers that can help determine which patients are at higher risk for developing VTE during treatment. By analyzing blood samples, the study will assess the expression of coagulation factors and evaluate the effectiveness of thromboprophylaxis strategies, particularly in relation to potential drug interactions. The ultimate goal is to improve patient outcomes by tailoring thromboprophylaxis based on individual risk profiles.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed multiple myeloma patients who have not previously received treatment.
Not a fit: Patients with a life expectancy of less than 6 months or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective prevention strategies for blood clots in multiple myeloma patients.
How similar studies have performed: Other studies have shown promising results in identifying biomarkers for thromboembolic risks in hematological conditions, suggesting this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient affiliated to a social security regimen or beneficiary of the same * Signed written informed consent form * Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment. Exclusion Criteria: * Pregnant women * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent * Refusing participation * Patient whose follow-up or life expectancy is less than 6 months.
Where this trial is running
Lyon and 1 other locations
- Hospices Civils de Lyon — Lyon, France (RECRUITING)
- CHU de Saint-Etienne — Saint-Etienne, France (RECRUITING)
Study contacts
- Principal investigator: Emilie Chalayer, MD — CHU de Saint-Etienne
- Study coordinator: Emilie Chalayer, MD
- Email: emilie.chalayer@chu-st-etienne.fr
- Phone: 04 77 91 70 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy, hematology, multiple myeloma, chemotherapy, thromboprophylaxis